Loading clinical trials...
Loading clinical trials...
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients With Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Conditions
Interventions
Afatinib
Biopsy Procedure
+5 more
Locations
1
United States
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, United States
Start Date
February 28, 2018
Primary Completion Date
December 6, 2022
Completion Date
January 15, 2027
Last Updated
April 23, 2026
NCT05969860
NCT04879121
NCT05053971
NCT03907475
NCT06311214
NCT04704661
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions